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Abstract
Background: Mucosal melanoma (MM) of head and neck (H&N) is a rare entity with a quite poor prognosis. 
Ballantyne’s staging system has been commonly used since 1970. In the 7th edition of the AJCC Staging Manual 
a new chapter for the staging of TNM Classification system for mucosal melanoma (MM) of the head and neck 
(H&N) has been introduced to reflect the particularly aggressive biological behavior of this neoplasm. The aim of 
this study was to analyze and compare among Ballantyne’s staging system vs TNM H&N in terms of overall sur-
vival (OS) and disease-free survival (DFS) in a consecutive population of patients with MM in a cancer centre. 
Material and Methods: Descriptive analysis of demographic, clinical and pathological variables of MM of the 
Head & Neck were performed. We compared the survival curves for both systems according to the Kaplan-Meier 
method using the Log-rank test. 
Results: An up-staging migration effect from Ballantyne’s localized disease to moderately and very advanced 
disease according to AJCC staging system. The 5-year DFS and OS for Ballantyne’s Localized Disease and AJCC 
Stage III were 31% and 36% vs. 47% and 50%, respectively. For locoregional disease the 5-year DFS / OS were 5% 
/ 10% for Bal-lantyne’s system vs. 13.8% / 17.8% and 0 / 0% for AJCC Stages IVA and IVB, respectively. 
Conclusions: In this series, the TNM staging system for MM of the H&N predicted better the prognosis of the 
disease when comparing with Ballantyne’s system. 
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Luna-Ortiz K, Aguilar-Romero M, Villavicencio-Valencia V, Zepeda-
Castilla E, Vidrio-Morgado H, Peteuil N, Mosqueda-Taylor A. Compara-
tive study between two different staging systems (AJCC TNM VS BAL-
LANTYNE’S) for mucosal melanomas of the Head & Neck. Med Oral 
Patol Oral Cir Bucal. 2016 Jul 1;21 (4):e425-30.   
 http://www.medicinaoral.com/medoralfree01/v21i4/medoralv21i4p425.pdf
Article Number: 21132          http://www.medicinaoral.com/
© Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946
eMail:  medicina@medicinaoral.com 
Indexed in: 
Science Citation Index Expanded
Journal Citation Reports
Index Medicus, MEDLINE, PubMed
Scopus, Embase and Emcare 
Indice Médico Español
doi:10.4317/medoral.21132
http://dx.doi.org/doi:10.4317/medoral.21132
Med Oral Patol Oral Cir Bucal. 2016 Jul 1;21 (4):e425-30.                                                                                                          AJCC TNM vs Ballantyne´s for Head and Neck mucosal melanomas
e426
Introduction
Mucosal melanoma is a rare malignant neoplasm that 
may develop from melanocytes present in the squamous 
or respiratory mucosa of the head & neck. It represents 
0.7 to 1% of all malignant melanomas, 6.7% of melano-
mas of the head & neck and 3.5% of sino-nasal malig-
nant neoplasms (1).  Mucosal melanoma has an estimat-
ed 5-year mortality risk of 68% to 89% which is worse 
than that for melanoma in other body areas (1-3).
There have been near 1000 case reports of mucosal 
melanomas of the head and neck worldwide in different 
case series. Most of them were single institution retro-
spective case series experiences (range 19 to 95 patients) 
that reported clinical, demographic and pathological 
characteristics of the disease and included the results of 
the treatments given to these patients collected through 
large periods of time (13-44 years); in general, survival 
is quite poor, even for the early-stage disease and local 
recurrence and distance metastases are the rule (4-13).
Lesions diagnosed in the paranasal sinuses and nasophar-
ynx are usually large, deeply invading tumours with a 
significant risk for distant metastases and death (nearly 
100%). Even though oral mucosal lesions are diagnosed 
in less advanced stages, they show a very aggressive be-
havior and about two thirds of the patients present a local 
recurrence or distant metastases within 1 year (14,15). 
Ballantyne’s staging system had been the most com-
monly used since 1970; it classifies lesions into three 
stages depending on the nature of the disease: Local, 
Regional or Disseminated. However this does not con-
sider the depth of invasion nor the local extension of the 
lesion (16). In 2004, this staging system was modified 
by Prasad et al. (17) who divided Stage I into 3 sub-
groups depending on the depth of tumor invasion. How-
ever, this subclassification has not gained widespread 
acceptance and it has not been correlated with progno-
sis in other centers (11). Staging used by the American 
Joint Committee on Cancer (AJCC) for cutaneous mela-
noma is not applicable for mucosal melanoma for sev-
eral reasons. Unlike cutaneous melanomas, the occult 
locations in which mucosal melanomas occur preclude 
sun exposure as a predisposing risk factor. Histologi-
cally, primary lesions are characterizaed by nested and 
single growth of typical melanocytes in the surround-
ing mucosa, others histopathologic features of mucosa 
melanoma include frequent angioinvasion and multi-
centricity. Whereas melanomas arising on skin without 
chronic sun damage had frequent mutations in BRAF, 
those mutations were much less common in melanomas 
occurring on acral skin, mucosal surfaces, and chroni-
cally sun-damaged skin. These findings suggest differ-
ing routes by which these tumors develop, which may 
ultimately impact response to treatment. The 7th edi-
tion of the AJCC Staging Manual has introduced a new 
chapter for the staging of mucosal melanoma of the head 
and neck in order to reflect the particularly aggressive 
biological behavior of this neoplasm. All lesions limited 
to the mucosa are considered T3. Advanced mucosal 
melanomas are classified as T4a (moderately advanced 
disease) and T4b (very advanced disease). Melanoma in 
situ is excluded because of the rarity of this entity.
The aim of this study was to describe the salient de-
mographic and clinico- pathological features of a series 
of MM of the Head & Neck, and compare them in a 
retrospective manner using the traditional Ballantyne’s 
staging system (15) and the AJCC staging TNM Clas-
sification system in terms of overall survival (OS) and 
disease-free survival (DFS) in a consecutive population 
of patients in a cancer referral centre in Mexico City.
Material and Methods
We conducted a retrospective study that included all 
the patients with diagnosis of mucosal melanoma of the 
head and neck admitted in a Cancer Referral Centre at 
Mexico City from April 1979 to December 2010. This 
study belongs to the line of research of mucosal mela-
noma, which has been approved by the Research and 
Ethics Committee of our institution.
A descriptive analysis of demographic, clinical and 
pathological variables considered relevant (such as, age, 
gender, primary site, and nodal and distant metastases) 
was performed.
Comparisons between both staging systems were done 
with the following approach: Ballantyne’s Local Dis-
ease vs. AJCC Stage III (T3N0M0), Ballantyne’s Re-
gional Disease vs. AJCC Stage IVA (T4aN0M0 and 
T3-T4aN1M0) and Stage IVB (T4b anyN M0). We also 
compared the OS and DFS between lesions depending 
on their primary tumour site (nasal cavity and paranasal 
sinuses vs. oral cavity).
We computed the survival curves (Disease-free survival 
[DFS] and overall survival [OS]) for both systems ac-
cording to the Kaplan-Meier method. In order to compare 
both staging systems we used the Log-rank statistical test 
among the groups and it was considered statistically sig-
nificant a two-tailed alpha value of P<0.05. We did not 
discuss about treatment given to the patients because it 
was not the primary objective of this work.
Results
We identified sixty-six patients (n=66), 38 females 
(57.6%) and 28 males (42.4%), with a small predomi-
nance of the women (female:male ratio; 1.35:1) and a 
mean age of 55.39 years (range, 28 to 93 y). Fifty-six 
patients (84.8%) presented to the hospital because of lo-
cal symptoms. The mean time between the appearance 
of the first symptoms and the time of presentation to 
the hospital was 9.64 months (range 1 to 60 months). 
Forty-one patients (62.1%) have been previously diag-
nosed or received any treatment before presenting to 
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this cancer referral centre. Mean size of the primary tu-
mour was 5.1 cm (range, 1 to 11 cm). Demographic and 
clinical variables as well as comparison between both 
staging systems (Ballantyne’s vs. AJCC) are shown 
in table 1, demonstrating an upstaging migration ef-
fect from Ballantyne’s Local stage to TNM Stage IVA, 
and at the same time, a reduction in TNM Stage III to 
15%. Therefore, there is an increment in Regional dis-
ease from Ballantyne’s 42.4% to 66.7% in TNM Stages 
IVA & IVB (an addition of 24.3%). Metastatic disease 
remains equal in both classifications. When computing 
disease-free survival (DFS) for Ballantyne’s Localized 
Table 1. Clinical and demographic characteristics at admission and Comparison between Ballantyne’s and AJCC.
Variable N (%)
Gender Male 28 (42.4)Female 38 (57.6)Symptoms at presentation No 10 (15.2)Yes 56 (84.4)
Previous treatments
No 25 (37.9)Yes 41 (62.1)
Types of treatment
Incisional biopsy 32 (48.5)Excisional biopsy 4 (6.1)Surgery 4 (6.1)Surgery +ChT + Radiation 1 (1.5)
Primary tumour site
Nasal cavity 33 (50)Oral cavity 26 (39.4)Paranasal sinuses 5   (7.6)Oropharynx 1   (1.5)Other sites (larynx) 1   (1.5)
Nodal metastases
No 32 (48.5)Yes 34 (51.5)Laterality Unilateral 19 (28.8)Bilateral 15 (22.7)
Distant metastases
No 59 (89.4)Yes 7   (10.6)
Sites
Lung 4   (6.1)Bone 1   (1.5)CNS 1   (1.5)Bone + lung 1  (1.5)Comparison Ballantyne N (%) AJCC N (%)
Clinical Stage
Local 31 (47) III 15 (22.7)
Regional 28 (42.4) IV A 36  (54.6) 44 (66.7)IV B 8 (12.1)
Metastatic 7 (10.6) IV C 7 (10.6)
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Disease we obtained a 5-year rate of 31% in comparison 
to the 47% observed for AJCC Stage III. In addition, it 
was calculated for locoregional disease a 5-year DFS of 
5% for Ballantyne’s system vs. 13.8 and 0% for AJCC 
Stages IVA and IVB, respectively (Figs. 1,2).
We obtained a 5-year overall survival (OS) for Ballan-
tyne’s Localized disease of 36% vs. 50% observed for 
AJCC (T3N0M0). The median overall survival for these 
groups was: 13 months for Localized disease according 
to Ballantyne’s and 23 months for AJCC Stage III.
There was a 5-year overall survival (OS) for locoregion-
al disease of 10% for Ballantyne’s and 17.8 and 0% for 
AJCC Stages IVA and IVB (Figs. 3,4). The mean over-
all survival for these groups was 7 months vs. 7 months 
and 5 months, respectively.
We did not found any difference between OS for AJCC 
Stages IVB and IVC of the 7th edition of the Staging 
Manual (Fig. 5). Differences in DFS and OS, observed 
between groups according to their stage [Ballantyne’s 
Local vs. Regional and AJCC Stages III vs. IVA vs. 
IVB] were statistically significant (P<0.05) with the ex-
ception of the DFS for the Ballantyne’s Local and Re-
gional disease groups.
The comparison between oral cavity vs. nasal cavity 
plus paranasal sinuses in terms of OS & DFS did not 
reach a statistical significant difference (P = 0.46 & 
0.29, respectively). 
Discussion
MM is a rare entity worldwide; despite this, it appears 
to be more frequent in Japan (18) and it does not seem 
to have any relation with solar radiation. Ballantyne’s 
Fig. 1. Disease-free survival (DFS) according to Ballant-
yne’s staging system (Kaplan-Meier).
Fig. 2. Disease-free survival (DFS) according to AJCC 7th 
edition staging system (Kaplan-Meier).
Fig. 3. Overall survival (OS) according to Ballantyne’s 
staging system (Kaplan-Meier).
Fig. 4. Overall survival (OS) according to AJCC 7th edition 
staging system (Kaplan-Meier).
Fig. 5. Overall survival (OS)  according to AJCC 7th edition staging 
system (Kaplan-Meier) for AJCC Stages IVB and IVC.
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staging was used for decades and it only considered 
three stages (Local, Regional and Disseminated dis-
ease), nevertheless being imperfect, Prasad et al. modi-
fied Ballantyne’s classification without reaching popu-
larity. In recent years, the AJCC Staging manual in its 
7th edition included a different classification system 
that adequately stages this disease and classifies MM as 
a minimum as Stage III without Stages I and II, which 
support the concept of being an advanced disease.
In this study we present a case series that included dif-
ferent mucosal subsites of the upper aero-digestive tract 
which allowed us to evaluate the utility of the TNM 
system for MM and to compare it with Ballantyne’s 
system. The primary tumour site in this series does 
not differ much with what has been described in other 
studies, as we found cases in nasal cavity and paranasal 
sinuses (57%), oral cavity (40%), and other sites (3%). 
Interestingly, more than one half of the patients present-
ed with nodal disease (51.5 %) and nearly one quarter 
(22.7%) presented bilateral neck disease, which is quite 
different with respect to the case series reported in the 
literature (9.8%) that have focused on the nasal cavity 
and paranasal sinuses but is accordance to case series 
with a greater relative proportion of primary tumours in 
the oral cavity (4-13). In this series metastatic disease at 
presentation was observed in 10.6%, which is similar to 
other reports in the literature which ranges from 5% to 
10.3% (14,15,17).
Mucosal melanoma presents with a deeper and larger 
local extension as compared to melanoma presenting 
in other sites. It has been observed a greater local re-
currence rate and a worse prognosis for patients with 
locally more advanced lesions which motivated the 
subclassification of the T stage in the AJCC 7th edi-
tion staging system and which is not taken into account 
in Ballantyne’s staging system. It is important to note 
that in the comparison of the less specific Ballantyne s´ 
system with the AJCC 7th edition system it can be ob-
served a stage migration effect which could explain 
the observed differences in DSF and OS between both 
staging systems. (Ballantyne’s Local/Regional disease 
47/42.4% vs. AJCC Stages III / IVA + IVB, 22.7/66.7%) 
(Table 1). 
Of note, even though the AJCC considers that nodal 
disease is not an important prognostic factor for the 
mucosal melanoma of the head and neck (in contrast to 
metastatic disease), any patient with regional disease is 
considered Clinical Stage IV. In this respect, in this pa-
per we found a statistical significant difference in terms 
of OS between the patients presenting with and without 
nodal disease (Figs. 1,3).
We did not find any statistical difference in relation to 
metastatic disease for both classifications. Similar to the 
findings of other series, prognosis in terms of DFS and 
OS was quite poor, especially in relation with recurrence 
of the disease and later development of distant disease. 
We did not observe any difference between AJCC 7th 
edition Stage IVB and IVC in terms of DFS or OS. Both 
groups of patients in this retrospective series had a very 
poor prognosis (5-year DFS and OS of 0%).  Possibly, 
this could mean one of two different things, prognosis 
for Stage IVb should be considered equivalent to that 
of metastatic disease (Stage IVc) or this study lacked a 
larger number of patients as to be able to find a differ-
ence between these two groups. 
In other studies (some based in national registries such 
as Finland or USA [SEER] it has been compared the 
classification system for nasal cavity and paranasal si-
nuses carcinoma (AJCC 6th or 7th edition), which has 
a greater specific weight given by the primary site of 
the tumour, to the proposed new system for the mucosal 
melanoma of the head and neck, which takes into ac-
count the greater aggressiveness of this entity and as-
signs a minimum stage for the primary tumour as T3. In 
some studies it has been shown that the staging system 
for mucosal melanoma has a better prognostic perfor-
mance, meanwhile others have found a better prognostic 
performance for the paranasal sinuses carcinoma stag-
ing system (19-21). So, It has been largely proposed that 
mucosal melanoma of the nasal cavity and paranasal si-
nuses has a different clinical behavior and prognosis in 
comparison with oral cavity, hence, most of the works 
published in the literature include only a subset of pa-
tients with primary tumours arising in nasal cavity and 
paranasal sinuses. Nevertheless, in the comparison we 
did in terms of OS and DFS we did not find any statis-
tical significant difference between these subgroups of 
patients. Both have quite poor prognosis, independently 
of the primary tumour site. In the work conducted by 
Michel et al. (21), they found a better prognostic per-
formance of the AJCC 7th edition staging system for 
carcinoma of the nasal cavity and paranasal sinuses ap-
plied to the mucosal melanomas arising in these prima-
ry sites in comparison with the specific mucosal mela-
noma staging system for all the head and neck region. In 
the series here presented, the comparison between oral 
cavity vs. nasal cavity plus paranasal sinuses in terms 
of OS & DFS did not reach a statistical significant dif-
ference (P = 0.46 & 0.29, respectively).
In the case series here presented, the AJCC 7th system 
for mucosal melanoma of the head and neck predicted the 
prognosis of the disease with a greater precision in com-
parison with Ballantyne’s staging system in MM without 
differentiating the site of presentation. Our results con-
tribute to the controversy, as we did not find any differ-
ence in the prognosis and so, we are in favor of a united 
staging system for all the head and neck region. 
Beyond the prognostic factors included in AJCC staging 
(TNM), several authors have found other clinical and 
pathological factors (i.e. age, primary tumour subsite 
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[nasal cavity and oral cavity vs. paranasal sinuses and 
other sites], histologic subtypes [i.e. pseudo-papillar or 
sarcomatoid subtypes], margins of resection, number of 
mitosis and ulceration) that have been correlated with 
prognosis and that could been added to the present clas-
sification in order to give an even more precise progno-
sis (3,12,17).
Conclusions
In our retrospective series of patients, the AJCC 7th 
edition staging system for the mucosal melanoma of 
the head and neck predicted with a greater precision 
the prognosis of the disease in comparison with Bal-
lantyne’s system. There is an upmigration from local 
to stage IVA when comparing Ballantyne s´ vs TNM, 
which rise the stage IVA and IVB more than 24%. No 
differences exist between both classifications for meta-
static disease and no difference was found between 
Stages IVb and IVc in the TNM system. According to 
our results TNM for MM can be applied to all MM in 
the head and Neck region.
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